Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Ardent Health Reports Lower Net Income for 2025

Ardent Health reported full-year 2025 net income of $230.1 million, down from $299.7 million in 2024, while adjusted EBITDA fell to $447.3 million from $498.5 million.

The company’s interest expense declined to $55.2 million from $65.6 million, and income tax expense eased to $56.2 million from $63.4 million. Depreciation and amortization rose to $155.7 million from $146.3 million.

Noncontrolling interest earnings increased to $94.3 million from $89.4 million, and equity-based compensation more than doubled to $39.3 million from $18.0 million. Epic-related expenses rose to $4.8 million from $3.2 million, while restructuring, exit and acquisition-related costs edged up to $13.3 million from $12.8 million.

Cybersecurity incident recoveries, net, were $22.7 million in 2025, slightly higher than $21.5 million in 2024. Loss on extinguishment and modification of debt increased to $7.3 million from $3.4 million. Other non-operating gains swung to a loss of $1.1 million from a gain of $4.9 million a year earlier.

For the fourth quarter, Ardent posted net income of $74.3 million and adjusted EBITDAR of $175.7 million. Rent expense payable to REITs totaled $41.8 million in the quarter and $164.3 million for the full year.

Adjusted EBITDAR for 2025 reached $611.6 million. Today the company's shares have moved 1.39% to a price of $10.91. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS